Membrane-bound Fas ligand requires RIP1 for efficient activation of caspase-8 within the death-inducing signaling complex

Journal of Immunology

Volumn 183, Issue 5, 2009, Pages 3278-3284

  Morgan, Michael J ^a   Kim, You Sun ^a,b   Liu, Zheng Gang ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CASPASE 8; CH 11 ANTIBODY; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS ANTIGEN; FAS LIGAND; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE RIP1; UNCLASSIFIED DRUG; CASP8 PROTEIN, HUMAN; CROSS LINKING REAGENT; FLAG PEPTIDE; HRB PROTEIN, HUMAN; IMMUNOGLOBULIN M; MEMBRANE PROTEIN; NUCLEOPORIN; PEPTIDE; RNA BINDING PROTEIN;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CELL DEATH; COMPARATIVE STUDY; CYTOTOXICITY; DRUG POTENTIATION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY;

ANTIBODIES; ANTIGENS, CD95; CASPASE 8; CELL DEATH; CROSS-LINKING REAGENTS; CYTOTOXICITY, IMMUNOLOGIC; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; ENZYME ACTIVATION; FAS LIGAND PROTEIN; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN M; JURKAT CELLS; MEMBRANE PROTEINS; NUCLEAR PORE COMPLEX PROTEINS; PEPTIDES; RNA-BINDING PROTEINS;

EID: 70349238897     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803428     Document Type: Article

References (30)

1. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14: 1129-1135.
2. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Downregulation of Fas ligand by shedding. Nat. Med. 4: 31-36.
3. Huang, D. C., M. Hahne, M. Schroeter, K. Frei, A. Fontana, A. Villunger, K. Newton, J. Tschopp, and A. Strasser. 1999. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc. Natl. Acad. Sci. USA 96: 14871-14876.
4. Henkler, F., E. Behrle, K. M. Dennehy, A. Wicovsky, N. Peters, C. Warnke, K. Pfizenmaier, and H. Wajant. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell Biol. 168: 1087-1098.
5. Villunger, A., D. C. Huang, N. Holler, J. Tschopp, and A. Strasser. 2000. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD. J. Immunol. 165: 1337-1343.
6. Legembre, P., M. Beneteau, S. Daburon, J. F. Moreau, and J. L. Taupin. 2003. Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J. Immunol. 171: 5659-5662. (Pubitemid 37467177)
7. Hohlbaum, A. M., S. Moe, and A. Marshak-Rothstein. 2000. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191: 1209-1220.
8. Yonehara, S., A. Ishii, and M. Yonehara. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169: 1747-1756.
9. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
10. Aoki, K., M. Kurooka, J. J. Chen, J. Petryniak, E. G. Nabel, and G. J. Nabel. 2001. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol. 2: 333-337.
11. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187: 1205-1213.
12. Stanger, B. Z., P. Leder, T. H. Lee, E. Kim, and B. Seed. 1995. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81: 513-523.
13. Holler, N., R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider, B. Seed, and J. Tschopp. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1: 489-495.
14. Kim, Y. S., M. J. Morgan, S. Choksi, and Z. G. Liu. 2007. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell 26: 675-687.
15. Wang, L., F. Du, and X. Wang. 2008. TNF-α induces two distinct caspase-8 activation pathways. Cell 133: 693-703.
16. Nicoletti, I., G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279.
17. Boatright, K. M., M. Renatus, F. L. Scott, S. Sperandio, H. Shin, I. M. Pedersen, J. E. Ricci, W. A. Edris, D. P. Sutherlin, D. R. Green, and G. S. Salvesen. 2003. A unified model for apical caspase activation. Mol. Cell 11: 529-541.
18. Ting, A. T., F. X. Pimentel-Muinos, and B. Seed. 1996. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15: 6189-6196.
19. Kelliher, M. A., S. Grimm, Y. Ishida, F. Kuo, B. Z. Stanger, and P. Leder. 1998. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8: 297-303.
20. Pobezinskaya, Y. L., Y. S. Kim, S. Choksi, M. J. Morgan, T. Li, C. Liu, and Z. Liu. 2008. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 9: 1047-1054.
21. Jin, Z., Y. Li, R. Pitti, D. Lawrence, V. C. Pham, J. R. Lill, and A. Ashkenazi. 2009. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721-735.
22. Bertrand, M. J., S. Milutinovic, K. M. Dickson, W. C. Ho, A. Boudreault, J. Durkin, J. W. Gillard, J. B. Jaquith, S. J. Morris, and P. A. Barker. 2008. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30: 689-700.
23. Mahoney, D. J., H. H. Cheung, R. L. Mrad, S. Plenchette, C. Simard, E. Enwere, V. Arora, T. W. Mak, E. C. Lacasse, J. Waring, and R. G. Korneluk. 2008. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. USA 105: 11778-11783.
24. + T cell activation through caspase-8-dependent NF-κ B activation. J. Immunol. 174: 5270-5278.
25. O'Donnell, M. A., D. Legarda-Addison, P. Skountzos, W. C. Yeh, and A. T. Ting. 2007. Ubiquitination of RIP1 regulates an NF-κB-independent cell-death switch in TNF signaling. Curr. Biol. 17: 418-424.
26. Kataoka, T., R. C. Budd, N. Holler, M. Thome, F. Martinon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, and J. Tschopp. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 10: 640-648.
27. Jin, Z., and W. S. El-Deiry. 2006. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol. Cell Biol. 26: 8136-8148.
28. Fisher, G. H., F. J. Rosenberg, S. E. Straus, J. K. Dale, L. A. Middleton, A. Y. Lin, W. Strober, M. J. Lenardo, and J. M. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946.
29. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I. A. Roberts, K. M. Debatin, A. Fischer, and J. P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349.
30. Thomas, L. R., R. L. Johnson, J. C. Reed, and A. Thorburn. 2004. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J. Biol. Chem. 279: 52479-52486.